Cary, NC – According to filings with the U.S. Securities and Exchange Commission, Apie Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Esther Alegria played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Apie Therapeutics

APIE Therapeutics is focused on the promising therapy targets of the Apelinergic System. The Apelin/APJ receptor is widely expressed in the endothelial of various organs and central to the pathophysiology of fibrosis, an underlying hallmark of many serious diseases. Drugs targeting the apelin receptor have been proposed for the treatment of Pulmonary, Cardiovascular and Metabolic diseases. Our team has partnered with top Apelin/APJ receptor and biased agonist researchers, medical professionals in the therapeutic area of interest and biopharma experts with extensive experience in clinical development thru commercialization to develop novel and best in class drug therapies.

To learn more about Apie Therapeutics, visit http://www.apie-therapeutics.com/

Contact:
Esther Alegria, Chief Executive Officer
919-594-1985
https://www.linkedin.com/in/esther-m-alegria-150b39114/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved